# A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

> **NCT02066909** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 77 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 0.15 mg PF-06649751
- **DRUG:** 0.5 mg PF-06649751
- **DRUG:** 0.5 mg PF-06649751
- **DRUG:** 1.5 mg PF-06649751
- **DRUG:** 1.5 mg PF-06649751 21 Days
- **DRUG:** 3.0 mg PF-06649751
- **DRUG:** 5.0 mg PF-06649751
- **DRUG:** 8.0 mg PF-06649751
- **DRUG:** 1.5 mg PF-06649751 in healthy Japanese subjects

## Key facts

- **NCT ID:** NCT02066909
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2015-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02066909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02066909, "A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02066909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*